Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Sichuan Baili Pharmaceutical Co., Ltd.
Peking University Cancer Hospital & Institute
ImmunoGenesis
Genentech, Inc.
Jiangsu HengRui Medicine Co., Ltd.
3D Medicines
TCRCure Biopharma Ltd.
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Children's National Research Institute
M.D. Anderson Cancer Center
Mabwell (Shanghai) Bioscience Co., Ltd.
Novartis
Biohaven Pharmaceuticals, Inc.
Sichuan Huiyu Pharmaceutical Co., Ltd
Georgetown University
Salubris Biotherapeutics Inc
Peking University Cancer Hospital & Institute
Emory University
St. Jude Children's Research Hospital
Advenchen Laboratories, LLC
Innovent Biologics Technology Limited (Shanghai R&D Center)
Binhui Biopharmaceutical Co., Ltd.
Axcynsis Therapeutics Pte Ltd
Suzhou Biomissile Pharmaceuticals Co., Ltd.
Memorial Sloan Kettering Cancer Center
Sanofi
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Ono Pharmaceutical Co. Ltd
Guangzhou Virotech Pharmaceutical Co., Ltd.
Sichuan Huiyu Pharmaceutical Co., Ltd
Shanghai Hengrui Pharmaceutical Co., Ltd.
PAQ Therapeutics, Inc.
Jiangsu HengRui Medicine Co., Ltd.
Sichuan University
Hebei Medical University Fourth Hospital
Memorial Sloan Kettering Cancer Center
SPARK Biopharma
Biohaven Pharmaceuticals, Inc.
Bliss Biopharmaceutical (Hangzhou) Co., Ltd
Nanjing Immunophage Biotech Co., Ltd
Sichuan Baili Pharmaceutical Co., Ltd.
Oxford BioTherapeutics Ltd
L & L Bio Co., Ltd., Ningbo, China
Shenzhen Geno-Immune Medical Institute
Jiaxing Pharmadax Genesis Pharmaceutical Technology Co.,Ltd.
Stanford University
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Bliss Biopharmaceutical (Hangzhou) Co., Ltd
University of California, San Francisco